Veterinary Medicines

Gallivac IB88 neo, bruistablet voor suspensie voor kippen

Authorised
  • Avian infectious bronchitis virus, type 793/B, strain CR88121, Live
Download as PDF

Product identification

Medicine name:
Gallivac IB88 neo, bruistablet voor suspensie voor kippen
Active substance:
  • Avian infectious bronchitis virus, type 793/B, strain CR88121, Live
Target species:
  • Chicken
Route of administration:
  • Nebulisation use

Product details

Active substance and strength:
  • Avian infectious bronchitis virus, type 793/B, strain CR88121, Live
    5.30
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Effervescent tablet
Withdrawal period by route of administration:
  • Nebulisation use
    • Chicken
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD07
Legal status of supply:
  • Medicinal product subject to medical prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Netherlands B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 116422
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 31/08/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."